GLOBEIMMUNE
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
GLOBEIMMUNE
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
1995-01-01
Address:
Louisville, Colorado, United States
Country:
United States
Website Url:
http://www.globeimmune.com
Total Employee:
11+
Status:
Active
Contact:
3036252710
Total Funding:
128.46 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics WordPress Content Delivery Network Font Awesome Domain Not Resolving Wordpress Plugins IPv6
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SternAegis
SternAegis investment in Venture Round - GlobeImmune
Generali Financial Holding
Generali Financial Holding investment in Series E - GlobeImmune
BSI SA
BSI SA investment in Series E - GlobeImmune
Wexford Capital
Wexford Capital investment in Series C - GlobeImmune
Eminent Venture Capital
Eminent Venture Capital investment in Series C - GlobeImmune
WRF Capital
WRF Capital investment in Series C - GlobeImmune
BNY Mellon
BNY Mellon investment in Series C - GlobeImmune
Boston Life Science Venture
Boston Life Science Venture investment in Series C - GlobeImmune
Richard King Mellon Foundation
Richard King Mellon Foundation investment in Series C - GlobeImmune
HealthCare Ventures
HealthCare Ventures investment in Series B - GlobeImmune
Official Site Inspections
http://www.globeimmune.com Semrush global rank: 5.81 M Semrush visits lastest month: 1.43 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
